ZIVO Stock Overview
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 2/6 |
| Dividends | 0/6 |
ZIVO Bioscience, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.00 |
| 52 Week High | US$19.08 |
| 52 Week Low | US$0.48 |
| Beta | 0.27 |
| 1 Month Change | 0% |
| 3 Month Change | -20.00% |
| 1 Year Change | -53.70% |
| 3 Year Change | -87.56% |
| 5 Year Change | -84.85% |
| Change since IPO | -99.49% |
Recent News & Updates
Shareholder Returns
| ZIVO | US Personal Products | US Market | |
|---|---|---|---|
| 7D | 0% | 4.1% | 1.2% |
| 1Y | -53.7% | -26.0% | 24.9% |
Price Volatility
| ZIVO volatility | |
|---|---|
| ZIVO Average Weekly Movement | 21.9% |
| Personal Products Industry Average Movement | 8.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ZIVO's share price has been volatile over the past 3 months.
Volatility Over Time: ZIVO's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 8 | John Payne | www.zivobioscience.com |
ZIVO Bioscience, Inc., a research and development company, engages in licensing and selling natural bioactive ingredients derived from its proprietary algae cultures to animal, human, and dietary supplement and medical food manufacturers. The company operates in the biotech and agtech sectors, with an intellectual property portfolio comprising proprietary algal and bacterial strains, biologically active molecules and complexes, production techniques, cultivation techniques, and patented or patent-pending inventions for applications in human and animal health. Its products indications include poultry gut health, bovine mastitis, canine joint health, human immune modification, algal biomass for human consumption, and biomass for supporting skin health / anti-aging.
ZIVO Bioscience, Inc. Fundamentals Summary
| ZIVO fundamental statistics | |
|---|---|
| Market cap | US$22.42m |
| Earnings (TTM) | -US$7.78m |
| Revenue (TTM) | US$27.65k |
811.0x
P/S Ratio-2.9x
P/E RatioIs ZIVO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZIVO income statement (TTM) | |
|---|---|
| Revenue | US$27.65k |
| Cost of Revenue | US$16.04k |
| Gross Profit | US$11.61k |
| Other Expenses | US$7.79m |
| Earnings | -US$7.78m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.77 |
| Gross Margin | 41.99% |
| Net Profit Margin | -28,127.25% |
| Debt/Equity Ratio | -10.9% |
How did ZIVO perform over the long term?
See historical performance and comparison